Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
Topline data anticipated in mid-2024
SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease
ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it has completed enrollment goal in the SIGNAL-AD clinical trial for people with mild dementia due to Alzheimer’s Disease (NCT04381468). Topline data from the study are expected in mid-2024, after the last enrolled patients will have received 12 months of treatment.
Related news for (VCNX)
- Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
- Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
- Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
- Vaccinex Announces Receipt of Delisting Notification from Nasdaq
- Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update